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Abstract
Objective: To determine the levels of brain-derived neurotrophic factor
(BDNF) in the serum of patients suffering from multiple sclerosis (MS) to eval-
uate the potential of serum BDNF as a biomarker for MS. Methods: Using a
recently validated enzyme-linked immunoassay (ELISA) we measured BDNF in
patients with MS (pwMS), diagnosed according to the 2001 McDonald criteria
and aged between 18 and 70 years, participating in a long-term cohort study
with annual clinical visits, including blood sampling, neuropsychological testing,
and brain magnetic resonance imaging (MRI). The results were compared with
an age- and sex-matched cohort of healthy controls (HC). Correlations between
BDNF levels and a range of clinical and magnetic resonance imaging variables
were assessed using an adjusted linear model. Results: In total, 259 pwMS and
259 HC were included, with a mean age of 44.42  11.06 and
44.31  11.26 years respectively. Eleven had a clinically isolated syndrome
(CIS), 178 relapsing remitting MS (RRMS), 56 secondary progressive MS
(SPMS), and 14 primary progressive MS (PPMS). Compared with controls,
mean BDNF levels were lower by 8 % (p˂0.001) in pwMS. The level of BDNF
in patients with SPMS was lower than in RRMS (p = 0.004). Interpretation:
We conclude that while the use of comparatively large cohorts enables the
detection of a significant difference in BDNF levels between pwMS and HC, the
difference is small and unlikely to usefully inform decision-making processes at
an individual patient level.
Introduction
Despite considerable efforts, personalized treatment of
MS patients is still empirical, largely based on clinical
practice and experience. In particular, paucity of readily
accessible biomarkers makes it difficult to predict the
individual course of the disease and potential treatment
response. Because of its multiple “trophic” roles in the
nervous system1-4 brain-derived neurotrophic factor
(BDNF) has received considerable attention as a potential
biomarker.3 In a large number of studies, the levels of
BDNF in human serum have been measured in multiple
conditions including neurodegenerative and psychiatric
diseases.3,4 Previous reports have also explored possible
links between levels of BDNF in serum and different MS
courses.5,6 In MS lesions, at the cellular level, beyond
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neurons, BDNF is primarily present in immune cells
including T cells and microglial cells, possibly also in
reactive astrocytes.7 A “trophic” interaction between infil-
trating immune cells and neurons has been repeatedly
discussed7-10. This included speculations that the reduced
availability of BDNF from immune cells and the resulting
loss of neuroprotective effects may contribute to neuro-
axonal degeneration and loss of neurons in chronic forms
of MS.11 Furthermore, the unexpected observation that
fingolimod, a drug frequently administered to MS
patients and targeting sphingosine-1 phosphate receptors,
increases the levels of BDNF in rodent neurons has fueled
speculations that some of the beneficial effects of the drug
may result from increased BDNF levels.12
So far, a range of technical issues have complicated
BDNF measurements in human serum, with for example
six commercially available ELISAs giving different results
with the same samples.13 In addition, in a considerable
majority of previous reports, the cohorts compared have
been too small to allow meaningful comparisons.
Recently, using a validated ELISA technique, we could
show that BDNF measurements in healthy individuals
yield sufficiently stable values for meaningful comparisons
if cohorts of sufficient sizes can be recruited.14
In this study, we compare BDNF levels in a large cohort of
MS patients (pwMS) with age- and sex-matched healthy
controls (HC) and relate the levels of serum BDNF cross-
sectionally and longitudinally to comprehensive clinical,
neuropsychological, and imaging measures to further
explore the potential of serum BDNF as biomarker for
pwMS.
Subjects
Data of pwMS and HC were obtained from participants
of an ongoing international MS cohort study (only local
patients were included) originally designed for a genome-
wide association analysis.15 This cohort study was
approved in 2003 by the local ethics committee (EKNZ,
Ethikkommission Nordwest- und Zentralschweiz, Basel,
Switzerland). All subjects gave written informed consent.
Material and Methods
Patients underwent annual comprehensive examinations at
baseline (BL) and at annual follow-up visits (Follow-up 1,
FU1); Follow-up 2, FU2; and so on for every following visit
(cohort study is still ongoing). At each visit, the following
assessments were performed: Neurostatus-UHB,16 cognitive
tests, questionnaires for fatigue and depression, blood sam-
pling, and standardized Magnetic Resonance Imaging
(MRI) scans. In HCs blood samples were only obtained at
BL and FU1 (no other assessments were performed). The
numbers of pwMS by visit were as follows: BL: 259, FU1:
241, FU2: 208, FU3:181, FU4: 169, FU5: 152, FU6: 144, FU7:
124, FU8: 99, FU9: 94, FU10: 28. The numbers of HC by visit
were: BL: 259, FU1: 226.
Cognition, Fatigue, and Depression
For cognition, Paced Auditory Serial Addition Test
(PASAT)17 and Symbol-Digit Modalities Test (SDMT)18
were performed at baseline (BL) and annually thereafter.
In addition after the third year of follow-up the Multiple
Sclerosis Inventarium Cognition (MUSIC),19 Fatigue Scale
for Motor functions and Cognition, FSMC20 and the
depression scale ADS-L21 were performed.
Magnetic resonance imaging
Head MRI scans were performed on all patients at base-
line and then yearly in a 1.5 T scanner (Magnetom
Avanto, Siemens Healthineers) equipped with a 12-ele-
ment head matrix coil. The yearly scanning protocol
included a transversal two-dimensional (2D) double-echo
proton density-/T2-weighted scan with a spatial resolu-
tion of 0.98x0.98x3 mm3, a sagittal three-dimensional
(3D) T1-weighted scan (isotropic 1mm3 resolution), and
a transversal 2D T1-weighted contrast enhanced spin-echo
scan (0.98x0.98x3 mm3).
At each time point white matter lesions (WML) were semi-
automatically segmented on PDw/T2w using intensity thresh-
olding with Amira 3.1.1 (Mercury Computer System) by trained
observers according to the standard operating procedures estab-
lished for the analysis of clinical phase II and phase III trials. The
WML volume (WMLV) was then computed for each MRI ses-
sion.22Normalized volumes ofwhole brain (NBV), whitematter
(NWMV), and grey matter (NGMV) were estimated by SIE-
NAX;23 deep gray matter structures (thalamus, globus pallidus,
and striatum) and hippocampuswere segmented using FIRST.24
Annualized percentage brain volume change (PBVC) was esti-
mated between BL and FU2 and between BL and FU5/6 with
SIENA,23 part of FSL.25 SIENA; SIENAX and FIRST were used
as implemented in the FMRIB software library (FSL version
6.0). The 3D T1w images covered also the upper cervical spinal
cord, approximately down to the C3-5 level. Cervical spinal cord
volume was analyzed by cord image analyser (cordial).26,27 Seg-
mentation was carried out over a 35-mm long spinal cord seg-
ment starting 27 mm below the cisterna pontis, which
corresponds to the spinal cord volume between the foramen
magnum and the C2/C3 intervertebral disc.
Blood sampling
Blood sampling was performed as described before,14 and
genotyping (including polymorphism rs6265) was done
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using the Sentrix HumanHaP550 Bead Chip.15 Blood
sampling for MS patients was performed annually (up to
10 years after BL), blood sampling for HC only at BL and
at FU1. BDNF levels were determined by ELISA using the
protocol described previously.14 Platelet (thrombocyte)
counts (Tc) and the volume percentage of red blood cells
in blood (hematocrit, Hct calculated from the number
and size of red blood cells) was analyzed with scatter and
morphology cytograms as the levels of BDNF depend on
both values.14
Statistical analysis
The analyses were performed in R version 3.6.3. All statis-
tical tests are performed two-tailed.
BDNF levels were log-normally distributed and there-
fore log-transformed prior to all analysis (in the figures
the raw data values are presented). Age, sex, Tc, and Hct
were included as covariates (if not described differently).
For the models, the back-transformed estimates (mult.ef-
fects) are presented together with 95 % confidence inter-
vals (CI). The CIs are estimated on the log-scale using
normal approximation and then back-transformed by
exponentiating.
The association between BDNF and clinical measures
(Expanded Disability Status Scale (EDSS), disease course,
disease groups and medication), neuropsychological mea-
sures (PASAT, SDMT, MUSIC, FSMC, and ADS-L) as
well as MRI measures (brain (whole and selected regions)
and spinal cord volume, T2-lesion volume, atrophy) were
all considered, details see below.
The BDNF rs6265 polymorphism was compared (Met/
Met vs. all others) using a Wilcoxon rank sum test with
continuity correction.
BDNF and clinical measures
Log-transformed BDNF levels at BL were compared
between HC and MS patients using a t-test. BDNF levels
at BL were modeled in a linear model. Course of disease
was included as factor using HC as reference level. Age,
sex, Tc count, and Hct were included as covariates.
Therefore estimates refer to the estimated difference in
the log-transformed BDNF-levels between the respective
level of disease course and HC.
For the analysis within the MS patient cohort, disease
group and disease duration were included as additional
covariates. For disease course RRMS was used as reference
level.
The association between BDNF levels at BL and EDSS
at BL was modeled as described above. In addition, the
association of BDNF (all measurements) and EDSS (all
measurements) was modeled using generalized estimating
equations (GEE) to account for the within-subject corre-
lations. Age and sex are included as covariates.
The association between BDNF levels at BL and medi-
cation at BL was modeled as described above. For medi-
cation the contrast “no medication” versus “medication”
was used. In addition RRMS as well as SPMS patients
without medication were compared to HC using a t-test
and a linear model including age, sex, Tc and Hct as
covariates. There was no sufficient data to account for
past treatment or treatment duration.
BDNF and neuropsychological measures
The association between BDNF levels and PASAT/SDMT
results at BL was assessed in a linear model. The model
was adjusted for progressive disease course (PPMS and
SPMS) versus relapsing forms (RRMS and CIS), age, sex,
Tc count, Hct and education (4 years or less, 5–10 years,
11–15 years, more than 15 years of school education).
The association was also assessed at FU1 considering the
change in BDNF levels between FU1 and BL.
For the results of MUSIC, ADS-L and the FSMC com-
ponents the same models were fitted at FU2, since this
was the first available measurement. The same was
repeated for the outcome variable at FU2 and the change
in the BDNF level between FU2 and FU1.
BDNF and MRI measures
The association between BDNF and T2w lesion volumes
was assessed using a linear model, where T2-lesion volume
was log-transformed and treated as a dependent variable.
The same was repeated for associations at FU1 and with
the change in BDNF levels between FU1 and BL.
The association between BDNF at FU1 and the number
of new/enlarging T2w lesions was modeled in a poisson
model using GEE to correct for the correlation of mea-
surements in the same individual. The association
between BDNF at BL and brain volume (NBV, NGMV,
NWMV), the volume of selected brain regions and the
volume of the spinal cord was assessed using a linear
model. The model was corrected for the covariates disease
course (using relapsing MS as a reference level vs. pro-
gressive MS), age, sex, Tc count, and Hct. The same was
done for the outcome variable at FU1 and the change in
the BDNF level between FU1 and BL.
In addition the association between brain volume at
FU1 and BDNF change between FU1 and BL was assessed
adjusting for the covariates brain volume at BL and age.
Annualized percentage brain volume change (PBVC)
was calculated based on measurements of brain volumes
at FU2 and at FU5/6 compared to BL. The association
between annualized 2-year brain atrophy and BDNF levels
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at BL, as well as changes between BL and FU2 were
assessed in a linear model, with brain atrophy being used
as a dependent variable. The model was also adjusted for
the covariate disease course and also applied to the annu-
alized FU5/FU6-brain atrophy. Some patients had two
measurements (FU5 brain atrophy and FU6 brain atro-
phy) and in these cases, the average of both measure-
ments was used. GEE are used to account for the
correlation between the measurements in the same indi-
vidual.
Results
In total, 259 patients with MS (pwMS) according to 2001
McDonald criteria28 and 259 age and sex-matched healthy
controls (HC) were included into this analysis. Partici-
pants were aged 18-70. The cohort study included all clin-
ical subtypes of MS28. There was no significant difference
regarding sex, age and the genetic polymorphism rs6265
between pwMS and HC at BL (Table 1).
The median BDNF level at BL was 29.13 ng/ml (mean
and sd: 29.41  7.24) in MS patients and 30.86 ng/ml
(mean and sd 32.69  8.33) in HC. The BL levels were
lower in patients with a secondary progressive course of
disease: median 28.49 ng/ml (mean and sd:
27.87  7.55). The summary statistics of BDNF levels at
BL are shown in Table 2. BDNF at BL was lower by the
factor 0.92 (8 %) in patients with MS compared to HC
(p˂0.001, 95 % CI [0.89;0.96]; Fig. 1). Patients with
RRMS and SPMS had lower BDNF levels compared to
HC (RRMS: P = 0.003, 95 % CI [0.90;0.98]; SPMS
P ˂ 0.001, 95 % CI [0.80; 0.91]). SPMS patients had
lower levels than RRMS patients (P = 0.004, 95 % CI
[0.82; 0.96]).
BDNF at BL was lower in patients with medication
(N = 162) when compared to untreated patients
(N = 97) when compared in a simple, t-test (Fig. 2).
However, after adjusting for age, sex, course of disease,
disease duration, Hct and Tc count, this was no longer
the case (P = 0.06, 95 % CI [0.89; 1.00]). There was no
difference between untreated RRMS patients and HC at
BL (P = 0.243, 95 % CI [0.90; 1.03]). However, BDNF
levels of untreated SPMS patients were lower than the
levels in HC (P = 0.026, 95 % CI [0.80; 0.99]).
No significant association between EDSS and BDNF
was detected.
With regard to PASAT, no significant association could
be detected with BDNF levels. With regard to the associa-
tion between changes over time, BDNF levels and PASAT
(BDNF FU 1 minus BDNF at BL) and PASAT at FU1 for
each increase of BDNF by 1 ng/mL within this year,
PASAT decreased by 0.33 points (0.33, P = 0.045, 95
% CI [0.65; 0.01]).
No association between BDNF (change) and the follow-
ing parameters could be found: SDMT, MUSIC, ADS-L,
FSMC, T2w-lesion volume, new/enlarging T2w lesions,
Table 1. Baseline characteristics of MS-patients and HC
Healthy controls MS patients P
MS patient subgroups (disease course)
CIS
RR
MS
SP
MS
PP
MS
N male (%) 81 (31.3) 78 (30.1) 0.849 4 (36.4) 40 (22.5) 27 (48.2) 7 (50)
Age (mean  (sd)) 44.31 (11.26) 44.42 (11.06) 0.909 36.04 (7.95) 41.74 (10.32) 53.77 (8.86) 47.70 (7.22)
Genetic Poly- morphism N (%) 0.446
AA (Met/Met) 10 (4.8) 7 (2.7) 1 (9.1) 5 (2.8) 1 (1.8) 0 (0)
AG (Met/Val) 69 (33.2) 81 (31.8) 1 (9.1) 55 (31.2) 22 (40.0) 3 (23.1)
GG (Val/Val) 129 (62.0) 167 (65.5) 9 (81.8) 116 (65.9) 32 (58.2) 10 (76.9)
Disease Duration
inyears(mean  (sd))
n.a. 8.58 (7.34) 1.70 (1.70) 7.89 (6.48) 12.64 (8.79) 5.93 (6.39)
EDSS (mean  (sd)) n.a. 1.41 (0.80) 2.61 (1.37) 4.95 (1.35) 4.64 (1.43)
No MS medication N (%) n.a. 97 (37.5) 8 (72.7) 56 (31.5) 19 (33.9) 14 (100)
MS medication N (%) n.a. 162 (62.5) 3 (27.3) 122 (68.5) 37 (66.1) 0 (0.0)
Fumaric acid 1 (0.4) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0)
Glatiramer acetate 33 (12.7) 0 (0.0) 29 (16.3) 4 (7.2) 0 (0.0)
Interferon b-1a i.m. 25 (9.7) 3 (27.3) 21 (11.8) 1 (1.8) 0 (0.0)
Interferon b-1a s.c. 40 (15.4) 0 (0.0) 35 (19.7) 5 (8.9) 0 (0.0)
Interferon b-1b s.c. 56 (21.6) 0 (0.0) 34 (19.1) 22 (39.3) 0 (0.0)
Mitoxantrone 7 (2.7) 0 (0.0) 2 (1.1) 5 (8.9) 0 (0.0)
CIS, clinically isolated syndrome; RRMS, relapsing remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS. P values refer to
HC versus all MS patients.
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NBV, NGMV, NWMV, regional brain volumes (Thala-
mus, Striatum, Globus pallidus, Hippocampus), spinal
cord volume, and annualized PBVC.
Concerning the genetic polymorphisms (Met/Met, Val/
Met, Val/Val) no significant difference in BDNF levels
could be detected when pooling all participants
(P = 0.269, Table 3). For details of all results see
Table S1.
Discussion
The main goal of this study was to explore whether or
not BDNF levels in MS patients reflect their condition
(based on clinical and magnetic resonance imaging vari-
ables) with measurements based on a recently developed
and validated BDNF ELISA in a large cohort of patients
with MS and matched healthy controls.
At the group level we found a significant reduction of
BDNF levels in pwMS compared to HC. This reduction
was more pronounced in patients with SPMS. These find-
ings at the group level are in line with some previous
reports,5,6,29 while other studies in smaller cohorts30 did
not confirm a difference.
No association between BDNF or BDNF change over
time could be found in any of the following investigated
variables: EDSS, PASAT, SDMT, MUSIC, ADS-L, FSMC,
T2w-lesion volume, new/enlarging T2w lesions, NBV,
NGMV, NWMV, regional brain volumes (Thalamus,
Striatum, Globus pallidus, Hippocampus), spinal cord
volume, and annualized PBVC.
Concerning the longitudinal changes of BDNF from BL
to FU1, 106 (40.9%) of the individuals retested after
12 months had BDNF serum values within 10 % of their
original reading (connected by blue lines seen in Fig. S1),
78 (30.1%) individuals showing 10-20% of changes (green
line) and 57 (22%) >20 % changes. This is in line with
the previously reported results from HC14. Looking at
patients with confirmed progression (EDSS 0: +1.5, EDSS
1-5: +1, EDSS ≥ 5.5: +0.5) over time no clear influence
on BDNF levels could be shown (Fig. S2). We conclude
that serum BDNF levels are stable over time and do not
reflect occurrence of clinical confirmed progression (the
latter statement based on a few cases (N = 54) only).
In the past, lower serum BDNF levels in patients suffer-
ing from a number of neurological conditions compared
to HC have been reported (such as depression,31
schizophrenia,32-38 Alzheimer’s,39,40 or Huntington’s dis-
ease.41,42 In autism spectrum disorders higher serum
levels were found43). These studies have been, at least in
part, driven by the assumption that BDNF levels in serum
may somehow reflect BDNF levels in the brain as diffu-
sion of BDNF from the brain was speculated to explain
its presence in the blood and platelets, in analogy with
the accumulation of serotonin by platelets. However,
there is no direct evidence for a brain-to-blood diffusion
of BDNF nor has the presence of a BDNF transporter
been demonstrated in platelets. Recently, a more plausible
explanation for the accumulation of BDNF in human pla-
telets has been presented with the demonstration that
megakaryocytes express the BDNF gene at significant
levels and fill up platelets with the protein,44 as is the case
for several other growth factors accumulated in plate-
lets.45 Conversely, if the brain were the source of BDNF
in serum, its concentration would be expected to be
higher in the cerebrospinal fluid (CSF), as is the case with
neurofilament light chains.46 Similar to neurofilaments,
BDNF is primarily contained in neurons in the central
nervous system47 and it is conceivable that its levels might
be influenced in this specific compartment as a result of
lesions accompanying MS; as has been demonstrated to
be the case for neurofilament light chains. It remains still
unclear to us if reliable techniques for measuring BDNF
in CSF do exist, but as far as known from the existing lit-
erature the levels of BDNF in CSF are very low.48 The
changes in BDNF levels in blood or serum are more likely
to reflect platelet activation and degranulation rather the
neuronal damage in conditions such as MS, mood disor-
ders, or neurodegeneration.49 In this study, we tried to
Table 2. Summary statistics of BDNF mean values in serum
Group N mean SD median IQR
MS Patients All 259 29.41 7.24 29.13 10.09
CIS 11 30.13 9.93 30.16 17.57
RRMS 178 29.52 6.73 29.20 9.45
SPMS 56 27.87 7.55 28.49 9.86
PPMS 14 33.67 8.72 32.34 10.08
All with medication 162 28.43 6.83 28.30 9.70
All without medication 97 31.05 7.62 29.88 10.51
Healthy Controls 259 32.69 8.33 30.86 9.09
BDNF values indicated in ng/ml. N, Number of patients; SD, standard deviation; IQR, Interquartile range; CIS, Clinically isolated Syndrome; RRMS,
Relapsing Remitting MS; SPMS, Secondary progressive MS; PPMS, Primary progressive MS.
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overcome some possible limitations: first of all we used a
previously described ELISA protocol,14 did also correct
for platelet counts and the hematocrit value and com-
pared a sufficient large cohort of patients with MS and
sex- and age-matched healthy volunteers. In addition the
possibility that the genetic polymorphism rs6265 could
explain the difference in serum levels could be excluded.
The replacement of valine by methionine in the pro-
domain of BDNF has received considerable attention
given its association with decreased performance in tests
of episodic and recall memory.50,51 As indicated in
Table 3, no significant differences could be observed
whereby the sample size could be too small for any firm
conclusions to be drawn. In addition we only examined
rs6265, one of the many SNPs in the vicinity of this gene.
Beyond the technical problems linked with the use of
Figure 1. BDNF levels at BL (ng/ml) in MS patients compared to HC (HC taken from Ref. 14). The geometric mean as presented in this figure
corresponds to the exponential of the arithmetic mean of log-transformed BDNF levels. P-value refers to comparison of log-transformed BDNF
values
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commercially available BDNF ELISAs sample size are also
likely to explain why in numerous studies exploring cor-
relations between BDNF levels and the rs6265 polymor-
phism, no clear conclusions could be drawn.52-54
Medication was considered to be a possible confounder
and could potentially have influenced the results as BDNF
at BL was lower in patients with medication (Fig. 2) when
compared in a simple t-test but after adjusting for age, sex,
course of disease, disease duration, Hct and Tc count this
was no longer the case. In addition BDNF levels of
untreated SPMS patients were lower than the levels in HC,
even when adjusted for age, therefore we assume that medi-
cation was not the only responsible factor for the observed
difference in BDNF serum levels, but there was no sufficient
data to account for past treatment or treatment duration.
Although the numbers of patients included in this
study should have been sufficient for reliable conclusions
on a group level, any conclusion on a subgroup level
(e.g., patients with confirmed progression over time)
could not be reliably drawn.
Figure 2. Comparison of log transformed BDNF levels by treatment (N = 259)
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From a clinical perspective the difference of serum
BDNF – although significant at the group level – is rela-
tively small and frequent overlap exists between BDNF
values in pwMS and HC at the individual level, further
limiting the value of BDNF levels as an aid to diagnosis
or as a prognostic marker for patients with MS.
In conclusion, the overall outcome of this study is that
serum levels of BDNF, even when measured in large
cohorts using a validated BDNF ELISA, probably neither
reflect nor predict disease progression and/or activity, and
therefore are unlikely to be useful as a reliable serum bio-
marker for pwMS to guide decision-making processes at
an individual level.
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Figure S1. BDNF serum levels at BL and FU1. Serum
BDNF values of participants at BL (n = 259) and FU1
(n = 241) visit. Measurements of the same subject are
connected by a colored line to indicate percentage change
in BDNF values between visits. Samples are separated on
the x-axis by age in years. A: RRMS and B: SPMS.
Figure S2. BDNF serum levels over time in patients with
confirmed progression (all visits marked as a black circle,
visits with confirmed progression marked red).
Table S1. Overview of all statistical analysis and results
(green: result statistically significant/ Magenta: result sta-
tistically not significant). 1 = Adjusted for age, sex, Tc,
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Hct. DC = Disease Course. DD = Disease Duration.
E = Education. If not otherwise indicated the values are
BL. BL = Baseline, FU1 = Follow-up 1, FU2 = Follow-up
2, FU3 = Follow-up 3, FU4 = Follow-up 4,
FU5 = Follow-up 5, FU6 = Follow-up 6. PBVC = Per-
centage Brain Volume Change, NBV = Normalized
(Total) Brain Volume, NGMV = Normalized Grey Matter
Volume, NWMV = Normalized White Matter Volume.
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